Evidence map›Paper›PMID 33119174›Full record

ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2021

Prognosis of bulky pTIIB cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching.

Masao Okadome, Rina Nagayama, Mototsugu Shimokawa, Kenzo Sonoda, Kumi Shimamoto, Toshiaki Saito

Open access · hybridAbstract readComparative Study
In one paragraph

Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Masao OkadomeGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-6179-7103
Rina NagayamaGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University, Ube, Yamaguchi, Japan.
Kenzo SonodaGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kumi ShimamotoGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Toshiaki SaitoGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
National Hospital Organization Kyushu Cancer Center · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether radical hysterectomy (RAH) can effectively treat true Stage IIB (pTIIB) cervical adenocarcinoma (AC) because FIGO (clinical) Stage IIB cervical cancer is rarely treated with RAH and radiotherapy has unfavorable effects on AC.

methodsWe retrospectively analyzed data for 82 patients with Stage pTIIB cervical cancer who underwent RAH at our institution between January 1997 and December 2017. The end points were disease-free survival (DFS) and overall survival (OS) among squamous cell carcinoma (SCC) (n = 60) and AC (n = 22) patients. Kaplan-Meier survival analysis with and without propensity score matching was conducted to identify the impact of RAH.

resultsPara-aortic lymph node metastasis and tumor diameter were significant factors for recurrence, and adjuvant chemotherapy prevented recurrence on multivariate analysis. After propensity score matching, there was no significant difference in DFS and OS between the groups. Five-year DFS and OS of the SCC group were 0.505 (95% confidence interval [CI] 0.268-0.702) and 0.619 (95% CI 0.351-0.803), respectively, and those of the AC group were 0.444 (95% CI 0.232-0.638) and 0.602 (95% CI 0.351-0.782), respectively.

conclusionBulky Stage pTIIB cervical cancer is hard to cure, but RAH plus adjuvant therapy might be an option for radio-resistant pTIIB cervical AC.

Indexed as

AdenocarcinomaCarcinoma, Squamous CellChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalFemaleHumansHysterectomyKaplan-Meier EstimateLymph NodesMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPropensity ScoreRetrospective StudiesAdenocarcinomaCervical cancerConcurrent chemoradiotherapyPropensity score matchingRadical hysterectomySquamous cell carcinoma

Identifiers

PMID33119174
PMCPMC7984353
OpenAlexW3097343941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.